Minor (2)Equipment & Facilities2023-09-2021 CFR 211.67(b)
Written procedures not established/followed
"Written procedures are not followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product."
Minor (2)Documentation & Records2023-09-2021 CFR 211.22(d)
Procedures not in writing, fully followed
"The responsibilities and procedures applicable to the quality control unit are not fully followed."
Minor (2)Documentation & Records2023-09-2021 CFR 211.113(b)
Procedures for sterile drug products
"Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed."
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Hiring Activity
Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No count for this company yet. The careers board we can read covers more than this business (100 postings on Nov 20, 2026), and we can't yet tell which of those roles belong to it. Why: the group's board only shows its ~100 newest postings across all units, so we can't separate this business's roles. We'd rather show no number than one that isn't really this company's.
"Item 2.02 Results of Operations and Financial Condition: On July 30, 2026, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) on its website at www.bms.com announcing its financial results for the second quarter of 2026. A copy of the Earnings Press Release is furnished pursuant to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein in its entirety. Other than the Earnings Press Release, the inform"
"Item 7.01 Regulation FD Disclosure: On July 30, 2026, the Company posted on its website at www.bms.com a presentation (the “Bristol Myers Presentation”) on certain financial and operating initiatives available for viewing during the Company’s conference call and webcast announcing its financial results for the second quarter of 2026 at 8:15 a.m. Eastern time. A copy of the Bristol Myers Presentation is furnished pursuant to this Item 7.01 as Exhibit 99.2 to this Current Report on Form 8-K and in"
"Our platforms are comprised of chemically-synthesized or small molecule drugs including protein degraders, drugs produced from biological processes, called “biologics”, ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics."
"CAR-T cell therapies are administered by intravenous infusion."
"Breyanzi
®
Breyanzi
(lisocabtagene maraleucel) is a CD19-directed genetically modified autologous CAR-T cell therapy indicated for the treatment of adult patients with relapsed or refractory LBCL after one or more lines of systemic therapy, including DLBCL not otherwise specified, high-grade B-cell lymphoma, primary mediastinal LBCL, grade 3B FL and relapsed or refractory FL after at least two prior lines of systemic therapy, relapsed or refractory CLL or SLL; relapsed or refractory MCL in patie"
"The acquisition will provide BMS with full rights to OTX-201, a preclinical
in vivo
CAR T-cell therapy currently in IND-enabling studies for autoimmune disease."
"rights to
Abecma
, a cell therapy for the treatment of adult patients with relapsed or refractory multiple myeloma."
"In October 2025, BMS entered into a definitive agreement to acquire Orbital Therapeutics, which will provide the Company with full rights to OTX-201, a preclinical
in vivo
CAR T-cell therapy currently in IND-enabling studies for autoimmune disease."
"rights to
Abecma
, a cell therapy for the treatment of adult patients with relapsed or refractory multiple myeloma."
"Breyanzi
(lisocabtagene maraleucel) — a CD19-directed genetically modified autologous CAR-T cell therapy indicated for the treatment of adult patients with relapsed or refractory LBCL after one or more lines of systemic therapy, including DLBCL not otherwise specified, high-grade B-cell lymphoma, primary mediastinal LBCL, grade 3B FL and relapsed or refractory FL after at least two prior lines of systemic therapy, relapsed or refractory CLL or SLL, and relapsed or refractory MCL in patients who "
"Abecma
(idecabtagene vicleucel) — is a BCMA genetically modified autologous CAR-T cell therapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cyclic ADP ribose hydrolase monoclonal antibody."
"rights to
Abecma
, a cell therapy for the treatment of adult patients with relapsed or refractory multiple myeloma."
"Breyanzi
(lisocabtagene maraleucel) — a CD19-directed genetically modified autologous CAR-T cell therapy indicated for the treatment of adult patients with relapsed or refractory LBCL after one or more lines of systemic therapy, including DLBCL not otherwise specified, high-grade B-cell lymphoma, primary mediastinal LBCL, grade 3B FL and relapsed or refractory FL after at least two prior lines of systemic therapy, relapsed or refractory CLL or SLL, and relapsed or refractory MCL in patients who "
"revenues increased 133% during the first quarter of 2025 primarily due to higher demand enabled by expanded manufacturing capacity, new indication launches and higher average net selling prices."
"Our platforms are comprised of chemically-synthesized or small molecule drugs including protein degraders; drugs produced from biological processes, called “biologics”; ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics."
"CAR-T cell therapies are administered by intravenous infusion."
"2
Breyanzi
®
Breyanzi
(lisocabtagene maraleucel) is a CD19-directed genetically modified autologous CAR-T cell therapy indicated for the treatment of adult patients with relapsed or refractory LBCL after one or more lines of systemic therapy, including DLBCL not otherwise specified, high-grade B-cell lymphoma, primary mediastinal LBCL, grade 3B FL and relapsed or refractory FL after at least two prior lines of systemic therapy, relapsed or refractory CLL or SLL, and relapsed or refractory MCL in"
"These changes primarily include (i) transforming R&D operations to accelerate pipeline delivery, (ii) enhancing our commercial operating model, and (iii) establishing a more responsive manufacturing network and expanding our cell therapy manufacturing capabilities."
"Our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases in the following core therapeutic areas: oncology and hematology with novel modalities in cell therapies, protein degraders, ADCs and radiopharmaceuticals; immunology with a focus on establishing new standards of care in pulmonology, rapidly advancing cell therapy into immunology diseases and transformational programs to control inflammation, reset immune memory and promote homeo"
"In addition, year-to-date, we have achieved significant advances in CAR-T cell therapy with the approval of
Breyanzi
in the U.S."
"These changes primarily include (i) transforming R&D operations to accelerate pipeline delivery, (ii) enhancing our commercial operating model, and (iii) establishing a more responsive manufacturing network and expanding our cell therapy manufacturing capabilities."
"Our focus is on discovering, developing and delivering transformational medicines for patients facing serious diseases in the following five core therapeutic areas: (i) oncology with a priority in certain tumor types, including diversification beyond IO; (ii) hematology with opportunities to expand leadership position in multiple myeloma, as well as broaden our portfolio across leukemias, lymphomas and non-malignant hematologic diseases; (iii) immunology with a focus in dermatology, rheumatology"
"In 2024, we achieved significant advances in CAR-T cell therapy with the approval of
Breyanzi
in the U.S."
"These changes primarily include (i) transforming R&D operations to accelerate pipeline delivery (ii) enhancing our commercial operating model, and (iii) establishing a more responsive manufacturing network and expanding our cell therapy manufacturing capabilities."
"Our focus is on discovering, developing and delivering transformational medicines for patients facing serious diseases in the following five core therapeutic areas: (i) oncology with a priority in certain tumor types, including diversification beyond IO; (ii) hematology with opportunities to expand leadership position in multiple myeloma, as well as broaden our portfolio across leukemias, lymphomas and non-malignant hematologic diseases; (iii) immunology with a focus in dermatology, rheumatology"
"In 2024, we achieved significant advances in the CAR-T cell therapy arena with the approval of
Abecma
in the U.S."
Frequently Asked Questions About Bristol Myers Squibb (CGT Mfg)
How many FDA inspections does Bristol Myers Squibb (CGT Mfg) have on record?
CDMO Signal tracks 8 FDA inspections for Bristol Myers Squibb (CGT Mfg), sourced from the FDA inspection database. See the full inspection history above.
Has Bristol Myers Squibb (CGT Mfg) received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Bristol Myers Squibb (CGT Mfg).
Does Bristol Myers Squibb (CGT Mfg) hold EMA or MHRA GMP certificates?
CDMO Signal tracks 1 EMA and 1 MHRA GMP certificates for Bristol Myers Squibb (CGT Mfg).
How many clinical programs is Bristol Myers Squibb (CGT Mfg) linked to?
Bristol Myers Squibb (CGT Mfg) is associated with 586 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Bristol Myers Squibb (CGT Mfg)'s CDMO Signal Score?
Bristol Myers Squibb (CGT Mfg) has a Signal Score of 87/100, based on quality, operations, financial stability, and capacity data.
Evaluating Bristol Myers Squibb (CGT Mfg) for a manufacturing program?
Use the free AI matchmaker to compare Bristol Myers Squibb (CGT Mfg) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.